Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2023 MPN Highlights
02 February 2024 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in myeloproliferative neoplasms (MPN) from ASH 2023
The Post-ASH 2023 MPN Highlights was supported by GSK and MorphoSys. Supporters have no influence over the production of content.
Session 1: JAK inhibitors and combinations
TRANSFORM-1: navitoclax with ruxolitinib vs ruxolitinib plus placebo
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
MANIFEST-2: pela + rux vs placebo + rux in JAKi treatment-naïve pts
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
FREEDOM2: fedratinib for myelofibrosis previously treated with RUX
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
XPORT-MF-034: selinexor + ruxolitinib in JAKi-naïve pts
Srinivas Tantravahi University of Utah, Salt Lake City, UT, United States
SIMPLIFY-1 & MOMENTUM: Longitudinal assessment of transfusion intensity
Ruben Mesa Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States
SIMPLIFY-1,-2, and MOMENTUM: RBC transfusion independence status
Vikas Gupta Princess Margaret Cancer Centre, Toronto, Canada
Panel discussion: JAK inhibitors and combinations
Session 2: Abstracts of broader significance
DALIAH: Interferon-α vs hydroxyurea in patients with MPN
Trine Alma Knudsen Zealand University Hospital, Roskilde, Denmark
Bomedemstat manages symptoms of ET while reducing cell burden
Joachim Joachim University Hospital Essen, Essen, Germany
Cytoreductive drugs upon outcomes in young adults with ET and PV
Yan Beauverd The Geneva University Hospitals, Geneva, Switzerland
ACE-536-MF-001: luspatercept in the treatment of anemia in pts with MF
Francesco Passamonti University of Insubria, Varese, Italy
TGF-β signaling by Ker-050 for MF and mitigating RUX-associated cytopenia
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Panel discussion: abstracts of broader significance
The Post-ASH 2023 MPN Highlights has been supported by:
